| Literature DB >> 32742710 |
Sarah Musa1, Sherif Osman2,3.
Abstract
BACKGROUND: Female infertility is a multifactorial condition constituting a worldwide public health problem. The ability to reproduce is an important product of any marriage, hence infertility may exert a negative impact on physical, financial, social and emotional wellbeing of affected couples. The cornerstone to the management of any disease, including infertility, is prevention. Identifying the modifiable risk factors of female infertility will aid at prevention, early detection, and treatment of medical conditions that can threaten fertility as well as promoting healthy behaviours that can preserve it. AIM: To explore the risk profile of infertility among Qatari women and compare risk factors distribution among primary vs. secondary infertility.Entities:
Keywords: Infertility; Modifiable; Prevention; Risk factors; Sexual transmitted disease
Year: 2020 PMID: 32742710 PMCID: PMC7385950 DOI: 10.1186/s40738-020-00080-5
Source DB: PubMed Journal: Fertil Res Pract ISSN: 2054-7099
Fig. 1Distributions of infertile participants according to fertility type, Women Hospital-Hamad Medical Corporation, 2018
Distribution of study participants according to their socio-demographic characteristics, Women Hospital-Hamad Medical Corporation, 2018
| Sociodemographic | Cases | Cases | Controls | ||
|---|---|---|---|---|---|
| Primary Infertility | Secondary Infertility | Infertility Total | n = 272(%) | ||
| 16–25 year | 12 (27.9) | 12 (12.9) | 24 (17.7) | 59 (21.7) | |
| 26–35 year | 23 (53.5) | 43 (46.2) | 66 (48.5) | 164(60.3) | |
| > 35 year | 8 (18.6) | 38 (40.9) | 46 (33.8) | 49 (18.0) | |
| Illiterate | 1 (2.3) | 5 (5.4) | 6 (4.4) | 2 (0.7) | |
| Primary | 6 (14.0) | 4 (4.3) | 10 (7.4) | 13 (4.8) | |
| Preparatory | 1 (2.3) | 11 (11.8) | 12 (8.8) | 13 (4.8) | |
| Secondary | 17 (39.5) | 40 (43.0) | 57 (41.9) | 131(48.2) | |
| University / higher | 18 (41.9) | 33 (35.5) | 51 (37.5) | 113(41.5) | |
| < 12.000 QR | 5 (11.6) | 6 (6.5) | 11 (8.1) | 5 (1.8) | |
| 12.000- < 25.000 QR | 13 (30.2) | 33 (35.5) | 46 (33.8) | 52 (19.1) | |
| | 25 (58.1) | 54 (58.1) | 79 (58.1) | 215(79.0) | |
| < 20 years | 6(14.0) | 26(28.0) | 32(23.5) | 86(31.6) | |
| 20 - < 25 | 18(41.9) | 37(39.8) | 55(40.4) | 113(41.5) | |
| 25 - < 30 | 10(23.3) | 23(24.7) | 33(24.3) | 59(21.7) | |
| 30 - < 35 | 4(9.3) | 5(5.4) | 9(6.6) | 12(4.4) | |
| | 5(11.6) | 2(2.2) | 7(5.1) | 2(0.7) | |
| 33 (76.7) | 60 (64.5) | 93 (68.4) | 232 (85.3) | ||
| Yes, occasionally | 4 (9.3) | 17 (18.3) | 21 (15.4) | 19 (7.0) | |
| Yes, frequently/seasonally | 4 (9.3) | 12 (12.9) | 16 (11.8) | 16 (5.9) | |
| Yes, most of the time | 2 (4.7) | 4 (4.3) | 6 (4.4) | 5 (1.8) | |
| 10(23.3) | 33 (35.5) | 43 (31.6) | 40 (14.7) | ||
* p < 0.05
SD Standard Deviation, QR Qatari Riyals
Distribution of study participants according to their lifestyle-related characteristics, Women Hospital-Hamad Medical Corporation, 2018
| Lifestyle history | Cases | Cases | Controls | ||
|---|---|---|---|---|---|
| Primary Infertility | Secondary Infertility | Infertility Total | n = 272 (%) | ||
| No | 41 (95.3) | 86 (92.5) | 127 (93.4) | 268 (98.5) | |
| Yes, currently | 1 (2.3) | 5 (5.4) | 6 (4.4) | 3 (1.1) | |
| Yes, previously | 1 (2.3) | 2 (2.2) | 3 (2.2) | 1 (0.4) | |
| Yes, | 2 (4.7) | 7 (7.5) | 9 (6.6) | 4 (1.5) | |
| No | 15 (35.9) | 42 (45.2) | 57 (42.0) | 153 (56.3) | |
| Yes, currently | 17 (39.5) | 41 (44.1) | 58 (42.6) | 103 (37.9) | |
| Yes, previously | 11 (25.6) | 10 (10.8) | 21 (15.4) | 16 (5.9) | |
| Yes, | 28 (65.1) | 51(54.8) | 79 (58.1) | 119 (43.8) | |
| No | 40 (93.0) | 84 (90.3) | 124 (91.2) | 263 (96.7) | |
| Yes | 3 (7.0) | 9 (9.7) | 12 (8.8) | 9 (3.3) | |
| No | 34 (79.1) | 70 (75.3) | 104 (76.5) | 238 (87.5) | |
| Yes | 9 (20.9) | 23 (24.7) | 32 (23.5) | 34 (12.5) | |
| No | 11 (25.6) | 25 (26.9) | 36 (26.5) | 203 (74.6) | |
| Yes | 32 (74.4) | 68 (73.1) | 100 (73.5) | 69 (25.4) | |
| No | 15 (34.9) | 38 (40.9) | 53 (39.0) | 232 (85.3) | |
| Yes | 28 (65.1) | 55 (59.1) | 83 (61.0) | 40 (14.7) | |
* p < 0.05
Distribution of study participants according to gynaecological history, Women Hospital-Hamad Medical Corporation, 2018
| Gynecological history | Cases | Cases | Controls | ||
|---|---|---|---|---|---|
| Primary Infertility | Secondary Infertility | Infertility Total | n = 272 (%) | ||
| Regular | 32 (74.4) | 65 (69.9) | 97 (71.3) | 256 (94.1) | |
| Irregular | 11 (25.6) | 28 (30.1) | 39 (28.7) | 16 (5.9) | |
| < 6 month | 1 (9.1) | 4 (14.3) | 5 (12.8) | 8 (50.0) | |
| ≥ 6 month | 10 (90.9) | 24 (85.7) | 34 (87.2) | 8 (50.0) | |
| < 21 days | 0 (0.0) | 1 (1.1) | 1 (0.7) | 0 (0.0) | |
| 21–35 days | 33 (76.7) | 61 (65.6) | 94 (69.1) | 252 (92.6) | |
| > 35 days | 10 (23.3) | 31 (33.3) | 41 (30.2) | 20 (7.4) | |
| No | 31 (72.1) | 72 (77.4) | 103 (75.7) | 260 (95.6) | |
| Yes | 12 (27.9) | 21 (22.6) | 33 (24.3) | 12 (4.4) | |
| No | 38 (88.4) | 84 (90.3) | 122 (89.7) | 272(100.0) | |
| Yes | 5 (11.6) | 9 (9.7) | 14 (10.3) | 0 (0.0) | |
| No | 30 (69.8) | 74 (79.6) | 104 (76.5) | 256 (94.1) | |
| Yes | 13 (30.2) | 19 (20.4) | 32 (23.5) | 16 (5.9) | |
| No | 31 (72.1) | 67 (72.0) | 98 (72.1) | 258 (94.9) | |
| Yes | 12 (27.9) | 26 (28.0) | 38 (27.9) | 14 (5.1) | |
| No | 27 (62.8) | 52 (55.9) | 79 (58.1) | 255 (93.8) | |
| Yes | 16 (37.2) | 41 (44.1) | 57 (41.9) | 17 (6.2) | |
| No | 36 (83.7) | 64 (68.8) | 100 (73.5) | 261 (96.0) | |
| Yes | 7 (16.3) | 29 (31.2) | 36 (26.5) | 11(4.0) | |
| No | 38 (88.4) | 80 (86.0) | 118 (86.8) | 269 (98.9) | |
| Yes | 5(11.6) | 13(14.0) | 18 (13.2) | 3 (1.1) | |
| No | 25 (58.1) | 55 (59.1) | 80 (58.8) | 262 (96.3) | |
| Yes | 18 (41.9) | 38 (40.9) | 56 (41.2) | 10 (3.7) | |
* p < 0.05
Distribution of secondary infertility participants and controls according to their obstetric history, Women Hospital-Hamad Medical Corporation, 2018
| Obstetric history | Secondary infertility | Controls | |
|---|---|---|---|
| No | 0 (0.0) | 42 (15.4) | |
| Yes | 93 (100.0) | 230 (84.6) | |
| < 5 years | 47 (50.5) | 194 (84.3) | |
| 5 - < 10 years | 38 (40.9) | 32 (14.0) | |
| 10 - < 15 years | 4 (4.3) | 4 (1.7) | |
| ≥ 15 years | 4 (4.3) | 0 (0.0) | |
- | |||
| Never | 80 (86.0) | 219 (95.2) | |
| Happened once or more | 13 (14.0) | 11 (4.8) | |
| Never | 35 (37.6) | 124 (53.9) | |
| Once | 35 (37.6) | 57 (24.8) | |
| Twice or more | 23 (24.8) | 49 (21.3) | |
| No | 83 (89.2) | 223 (97.0) | |
| Yes | 10 (10.8) | 7 (3.0) | |
| No | 55 (59.1) | 192 (70.6) | |
| Yes | 38 (40.9) | 80 (29.4) | |
* p < 0.05
Distribution of study participants according medical/medication history, Women Hospital-Hamad Medical Corporation, 2018
| Medical/ Medication history | Cases | Cases | Controls | ||
|---|---|---|---|---|---|
| Primary Infertility | Secondary Infertility | Infertility Total | n = 272 (%) | ||
| No | 35 (81.4) | 75 (80.6) | 110 (80.9) | 242 (89.0) | |
| Yes | 8 (18.6) | 18 (19.4) | 26 (19.1) | 30 (11.0) | |
| No | 34 (79.1) | 78 (83.9) | 112 (82.4) | 255 (93.8) | |
| Yes | 9 (20.9) | 15 (16.1) | 24 (17.6) | 17 (6.2) | |
| No | 40 (93.0) | 88 (94.6) | 128 (94.1) | 270 (99.3) | |
| Yes | 3 (7.0) | 5 (5.4) | 8 (5.9) | 2 (0.7) | |
| No | 21 (48.8) | 43 (46.2) | 64 (47.1) | 220 (80.9) | |
| Yes | 22 (51.2) | 50 (53.8) | 72 (52.9) | 52 (19.1) | |
| No | 37 (86.0) | 86 (92.5) | 123 (90.4) | 261 (96.0) | |
| Yes | 6 (14.0) | 7 (7.5) | 13 (19.6) | 11 (4.0) | |
| No | 41 (95.3) | 84 (94.3) | 125 (91.9) | 263 (96.7) | |
| Yes | 2 (4.7) | 9 (9.7) | 11 (8.3) | 9 (3.3) | |
| No | 42 (97.7) | 84 (90.3) | 126(92.6) | 267 (98.2) | |
| Yes | 1 (2.3) | 9 (9.7) | 10 (7.4) | 5 (1.8) | |
| No | 15 (34.9) | 19 (20.4) | 34 (25.0) | 260 (95.6) | |
| Yes | 28 (65.1) | 74 (79.6) | 102(75.0) | 12 (4.4) | |
| No | 40 (93.0) | 78 (83.9) | 118(86.8) | 261 (96.0) | |
| Yes | 3 (7.0) | 15 (16.1) | 18 (13.2) | 11 (4.0) | |
| No | 42 (97.7) | 81 (87.1) | 123(90.4) | 267 (98.2) | |
| Yes | 1 (2.3) | 12 (12.9) | 13 (9.6) | 5 (1.8) | |
* p < 0.05
NSAID Non-Steroidal Anti Inflammatory Drugs
Xenical® is the trade name for Orlistat, Meridia® is the trade name for Sibutranine
Distribution of study participants according medical/medication history, Women Hospital-Hamad Medical Corporation, 2018
| Cases | Cases | Controls | |||
|---|---|---|---|---|---|
| Primary Infertility | Secondary Infertility | Infertility Total | |||
| No | 38 (88.4) | 45 (48.4) | 83 (61.0) | 88 (32.4) | |
| Yes | 5 (11.6) | 48 (51.6) | 53 (39.0) | 184 (67.6) | |
| No | 2 (40.0) | 13 (27.1) | 15 (28.3) | 92 (50.0) | |
| Yes | 3 (60.0) | 35 (72.9) | 38 (71.7) | 92 (50.0) | |
| No | 3 (60.0) | 39 (81.2) | 42 (79.2) | 106 (57.6) | |
| Yes | 2 (40.0) | 9 (18.8) | 11 (20.8) | 78 (42.4) | |
| No | 18 (41.9) | 38 (40.9) | 56 (41.2) | 51 (18.8) | |
| Yes | 25 (58.1) | 55 (59.1) | 80 (58.8) | 221 (81.2) | |
| No | 24 (55.8) | 51 (54.8) | 75 (55.1) | 71 (26.1) | |
| Yes | 19 (44.2) | 42 (45.2) | 61 (44.9) | 201 (73.9) | |
* p < 0.05
Distribution of study participants according to their family history, Women Hospital-Hamad Medical Corporation, 2018
| Family history | Cases | Cases | Controls | ||
|---|---|---|---|---|---|
| Primary Infertility | Secondary Infertility | Infertility Total | n = 272 (%) | ||
| No | 24 (55.8) | 55 (59.1) | 79 (58.1) | 197 (72.4) | |
| Yes | 19 (44.2) | 38 (40.9) | 57 (41.9) | 75 (27.6) | |
| No | 28 (65.1) | 63 (67.7) | 91 (66.9) | 227 (83.5) | |
| Yes | 15 (34.9) | 30 (32.3) | 45 (33.1) | 45 (16.5) | |
| No | 30 (69.8) | 69 (74.2) | 99 (72.8) | 221 (81.3) | |
| Yes | 13 (30.2) | 24 (25.8) | 37 (27.2) | 51 (18.8) | |
| No | 34 (79.1) | 75 (80.6) | 109 (80.1) | 246 (90.4) | |
| Yes | 9 (20.9) | 18 (19.4) | 27 (19.9) | 26 (9.6) | |
| No | 16 (37.2) | 35 (37.6) | 51 (37.5) | 197 (72.4) | |
| Yes | 27 (62.8) | 58 (62.4) | 85 (62.5) | 75 (27.6) | |
| No | 30 (69.8) | 55 (59.1) | 85 (62.5) | 219 (80.5) | |
| Yes | 13 (30.2) | 38 (40.9) | 51 (37.5) | 53 (19.5) | |
* p < 0.05
Distribution of study participants according to their WHO-BMI classification/ PHQ-2 score, Women Hospital-Hamad Medical Corporation, 2018
| WHO-BMI classification | Cases | Cases | Controls | ||
|---|---|---|---|---|---|
| Primary Infertility | Secondary Infertility | Infertility Total | n = 272 (%) | ||
| 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (2.6) | ||
| 6 (13.9) | 15 (16.1) | 21 (15.4) | 68 (25.0) | ||
| 14 (32.6) | 27 (29.0) | 41 (30.2) | 98 (36.0) | ||
| 23 (53.5) | 51 (54.9) | 74 (54.4) | 99 (36.4) | ||
| Negative | 38 (88.4) | 79 (84.9) | 117 (86.0) | 257 | |
| Positive | 5 (11.6) | 14 (15.1) | 19 (14.0) | (94.5) 15 (5.5) | |
* p < 0.05
Fig. 2Distribution of some risk factors among primary and secondary infertile participants, Women Hospital-Hamad Medical Corporation, 2018
Fig. 3Main significant risk factors of infertility among Qatari women derived from the bivariate analysis, Women Hospital-Hamad Medical Corporattion, 2018
Infertility risk factors: Results of the bivariate and multivariate logistic regression analysis, Women Hospital-Hamad Medical Corporation, 2018
| Independent risk factors | Crude Odd ratio | 95% Confidence interval (CI) | Adjusted Odd ratio (aOR) | 95% Confidence interval (CI) | |
|---|---|---|---|---|---|
| 2.31 | 1.24–4.29 | 3.72 | 0.008* | 1.41–9.83 | |
| 1.78 | 1.18–2.70 | 2.44 | 0.008* | 1.26–4.73 | |
| 8.17 | 5.11–13.05 | 4.65 | 0.001* | 2.43–8.91 | |
| 9.08 | 5.62–14.69 | 4.87 | 0.001* | 2.54–9.32 | |
| 6.43 | 3.44–12.04 | 4.20 | 0.031* | 1.14–15.49 | |
| Lower abdominal/pelvic pain | 10.82 | 3.95–19.67 | 3.46 | 0.002* | 1.57–7.63 |
| Abnormal vaginal discharge | 8.54 | 4.19–17.44 | 3.32 | 0.019* | 1.22–9.03 |
| Dyspareunia | 18.44 | 8.95–37.60 | 7.04 | 0.001* | 2.76–17.95 |
| 7.71 | 3.22–18.47 | 5.45 | 0.003* | 1.75–16.95 | |
| 4.9 | 2.78–8.65 | 5.8 | 0.001* | 3.28–10.21 | |
| 3.24 | 1.39–7.52 | 2.63 | 0.042* | 1.04–6.67 | |
| 1.94 | 1.18–3.17 | 2.11 | 0.008* | 1.21–3.68 | |
| 3.84 | 1.42–10.42 | 3.75 | 0.016* | 1.27–11.06 | |
* p < 0.05
a Model I: X2 (12) = 264, p < 0.001, Nagelkerke R = 0.661
b Model II: X2 (4) = 57.3, p < 0.001, Nagelkerke R = 0.233
Model I included comparison between total cases (n = 136) and total controls (n = 272)
Model II included comparison between secondary infertile women (n = 93) and only controls who reported previous conception (n = 230)